Antidepressant use and colorectal cancer risk: A systematic review and meta-analysis of epidemiological studies.

Eur NeuropsychopharmacolMay 17, 2026 (epub)
Clinical ResearchGastroenterologyPsychiatry

Cuiling Wei, Oscar Mahasriariyawong, Peng Wu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between antidepressant use and colorectal cancer (CRC) risk across 15 observational studies. The analysis revealed a significantly lower CRC risk associated with antidepressant use, with a pooled odds ratio of 0.88 (95% CI: 0.87, 0.95) and a pooled hazard ratio of 0.85 (95% CI: 0.74, 0.97), particularly for selective serotonin reuptake inhibitors and tricyclic antidepressants.

Key findings

  • Pooled odds ratio for CRC risk associated with antidepressant use was 0.88 (95% CI: 0.87, 0.95).
  • Pooled hazard ratio for CRC risk was 0.85 (95% CI: 0.74, 0.97).
  • SSRIs and TCAs both had a pooled odds ratio of 0.90 (95% CI: 0.84, 0.96) for CRC risk.
  • No significant relationship was found between antidepressant exposure patterns and CRC risk.

Why it matters

Understanding the potential protective effects of antidepressants against colorectal cancer can inform clinical decision-making, particularly in patients with comorbid mental health conditions. This dual benefit may influence treatment strategies and patient counseling.

Source

PubMed · PMID 42143914

Published in Eur Neuropsychopharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.